Abstract: Liver cancer ranks the sixth in most common malignant tumor and the fourth in leading cause of tumor-related death worldwide, of which hepatocellular carcinoma (hepatocellular carcinoma, HCC) accounts for 90%. More than 80% of HCC occurs in patients with hepatitis and cirrhosis. And only 20% of HCC patients can be treated with surgical resection, liver transplantation or radiofrequency ablation, while the patients with advanced HCC can not receive radical treatment, so their survival rate is low. In recent years, molecular targeted drug therapy has become a research hotspot, and the drug can exert its anticancer effect by specifically binding to carcinogenic sites. At present, the targeting drugs of anti-HCC are mainly divided into first-line drugs and second-line drugs, of which the first-line drugs mainly include sorafenib and lenvatinib, and the second-line drugs mainly include regofinib, carbotinib and ramoruximab.